Literature DB >> 19339428

Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients.

José L Nishiura1, Rodrigo F C A Neves, Samara R M Eloi, Susan M L F Cintra, Sergio A Ajzen, Ita P Heilberg.   

Abstract

BACKGROUND AND OBJECTIVES: Nephrolithiasis (LIT) is more prevalent in patients with autosomal dominant polycystic kidney disease (ADPKD) than in the general population. Renal ultrasonography may underdetect renal stones because of difficulties imposed by parenchymal and/or cyst wall calcifications. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 125 patients with ADPKD underwent ultrasonography and unenhanced computed tomography (CT) scan, routine blood chemistry, and spot and 24-h urine collections.
RESULTS: CT scan detected calculi in 32 patients, including 20 whose previous ultrasonography revealed no calculi. The percentage of hypocitraturia was high but not statistically different between patients with ADPKD+LIT or ADPKD. Hyperuricosuria and distal renal tubular acidosis were less prevalent but also did not differ between groups, whereas hyperoxaluria was significantly higher in the former. Hypercalciuria was not detected. Renal volume was significantly higher in patients with ADPKD+LIT versus ADPKD, and a stepwise multivariate logistic regression analysis showed that a renal volume >or=500 ml was a significant predictor of LIT in patients with ADPKD and normal renal function, after adjustments for age and hypertension.
CONCLUSIONS: CT scan was better than ultrasonography to detect LIT in patients with ADPKD. Larger kidneys from patients with ADPKD were more prone to develop stones, irrespective of the presence of metabolic disturbances.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339428      PMCID: PMC2666433          DOI: 10.2215/CJN.03100608

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  26 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kimberly K McFann; Ann M Johnson
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

3.  Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease.

Authors:  S A Grampsas; P S Chandhoke; J Fan; M A Glass; R Townsend; A M Johnson; P Gabow
Journal:  Am J Kidney Dis       Date:  2000-07       Impact factor: 8.860

4.  [Serum creatinine determination without protein precipitation].

Authors:  H Bartels; M Böhmer; C Heierli
Journal:  Clin Chim Acta       Date:  1972-03       Impact factor: 3.786

5.  Tubular function in adult polycystic kidney disease.

Authors:  H Preuss; K Geoly; M Johnson; A Chester; A Kliger; G Schreiner
Journal:  Nephron       Date:  1979       Impact factor: 2.847

6.  Pathophysiologic basis for normouricosuric uric acid nephrolithiasis.

Authors:  Khashayar Sakhaee; Beverley Adams-Huet; Orson W Moe; Charles Y C Pak
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

7.  A novel mutation in the anion exchanger 1 gene is associated with familial distal renal tubular acidosis and nephrocalcinosis.

Authors:  Lara Cheidde; Teresa Cristina Vieira; Paulo Roberto Moura Lima; Sara Teresinha Ollala Saad; Ita Pfeferman Heilberg
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

8.  Pain patterns in patients with polycystic kidney disease.

Authors:  Zahid H Bajwa; Khuram A Sial; Atif B Malik; Theodore I Steinman
Journal:  Kidney Int       Date:  2004-10       Impact factor: 10.612

Review 9.  Cystic disease of the kidney.

Authors:  Patricia D Wilson; Beatrice Goilav
Journal:  Annu Rev Pathol       Date:  2007       Impact factor: 23.472

10.  Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine.

Authors:  P Fossati; L Prencipe; G Berti
Journal:  Clin Chem       Date:  1980-02       Impact factor: 8.327

View more
  31 in total

1.  Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

Authors:  Matteo Bargagli; Nasser A Dhayat; Manuel Anderegg; Mariam Semmo; Uyen Huynh-Do; Bruno Vogt; Pietro Manuel Ferraro; Daniel G Fuster
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

2.  Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Authors:  Jacob A Torres; Mina Rezaei; Caroline Broderick; Louis Lin; Xiaofang Wang; Bernd Hoppe; Benjamin D Cowley; Vincenzo Savica; Vicente E Torres; Saeed Khan; Ross P Holmes; Michal Mrug; Thomas Weimbs
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

3.  A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease.

Authors:  Bharathi V Reddy; Arlene B Chapman
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-07       Impact factor: 8.237

Review 4.  Evaluation and management of pain in autosomal dominant polycystic kidney disease.

Authors:  Marie C Hogan; Suzanne M Norby
Journal:  Adv Chronic Kidney Dis       Date:  2010-05       Impact factor: 3.620

5.  ADPKD, Tolvaptan, and Nephrolithiasis Risk.

Authors:  Ewout J Hoorn; Robert Zietse
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

Review 6.  Sensing of tubular flow and renal electrolyte transport.

Authors:  Eric H J Verschuren; Charlotte Castenmiller; Dorien J M Peters; Francisco J Arjona; René J M Bindels; Joost G J Hoenderop
Journal:  Nat Rev Nephrol       Date:  2020-03-03       Impact factor: 28.314

7.  Percutaneous nephrolithotomy in polycystic kidney disease: is it safe and effective?

Authors:  Aneesh Srivastava; Rajesh Bansal; Alok Srivastava; Samit Chaturvedi; Priyadarshi Ranjan; M S Ansari; Abhishek Yadav; Rakesh Kapoor
Journal:  Int Urol Nephrol       Date:  2011-11-20       Impact factor: 2.370

8.  ALG9 Mutation Carriers Develop Kidney and Liver Cysts.

Authors:  Whitney Besse; Alex R Chang; Jonathan Z Luo; William J Triffo; Bryn S Moore; Ashima Gulati; Dustin N Hartzel; Shrikant Mane; Vicente E Torres; Stefan Somlo; Tooraj Mirshahi
Journal:  J Am Soc Nephrol       Date:  2019-08-08       Impact factor: 10.121

9.  Determination of urinary lithogenic parameters in murine models orthologous to autosomal dominant polycystic kidney disease.

Authors:  Renato Ribeiro Nogueira Ferraz; Jonathan Mackowiak Fonseca; Gregory George Germino; Luiz Fernando Onuchic; Ita Pfeferman Heilberg
Journal:  Urolithiasis       Date:  2014-05-10       Impact factor: 3.436

Review 10.  A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

Authors:  Niek F Casteleijn; Folkert W Visser; Joost P H Drenth; Tom J G Gevers; Gerbrand J Groen; Marie C Hogan; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.